523 related articles for article (PubMed ID: 29856800)
1. Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.
Depré F; Aboud N; Mayer B; Salama A
PLoS One; 2018; 13(6):e0198184. PubMed ID: 29856800
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
Zaja F; Barcellini W; Cantoni S; Carpenedo M; Caparrotti G; Carrai V; Di Renzo N; Santoro C; Di Nicola M; Veneri D; Simonetti F; Liberati AM; Ferla V; Paoloni F; Crea E; Volpetti S; Tuniz E; Fanin R
Am J Hematol; 2016 May; 91(5):E293-5. PubMed ID: 26910388
[TBL] [Abstract][Full Text] [Related]
3. [New treatment options for primary immune thrombocytopenia].
Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
[No Abstract] [Full Text] [Related]
6. Infection-related transient loss of response and other early side effects in chronic ITP during treatment with thrombopoietin mimetics.
Meyer O; Salama A
Onkologie; 2011; 34(1-2):10-3. PubMed ID: 21346379
[TBL] [Abstract][Full Text] [Related]
7. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
[TBL] [Abstract][Full Text] [Related]
8. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
9. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
Donga PZ; Bilir SP; Little G; Babinchak T; Munakata J
J Med Econ; 2017 Nov; 20(11):1200-1206. PubMed ID: 28882075
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series.
Poston JN; Gernsheimer TB
Int J Hematol; 2019 Aug; 110(2):255-259. PubMed ID: 30972617
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
Agnelli Giacchello J; Valeri F; Boccadoro M; Borchiellini A
Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
[TBL] [Abstract][Full Text] [Related]
12. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
Mori M; Kato M; Koh K; Hanada R
Rinsho Ketsueki; 2015 May; 56(5):511-3. PubMed ID: 26062675
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
[TBL] [Abstract][Full Text] [Related]
14. Management of immune thrombocytopenia in elderly patients.
Lucchini E; Fanin R; Cooper N; Zaja F
Eur J Intern Med; 2018 Dec; 58():70-76. PubMed ID: 30274902
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series.
Vianello F; D'Amore F; Lombardi AM; Caputo I; Friziero A; Da Dalt G
Blood Coagul Fibrinolysis; 2019 Sep; 30(6):295-299. PubMed ID: 31259778
[TBL] [Abstract][Full Text] [Related]
16. Two new drugs for chronic ITP.
Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
[TBL] [Abstract][Full Text] [Related]
17. [Trombopag for chronic immune thrombocytopenia in a patient previously treated with romiplostim].
Rodríguez Vargas B; Serna Pérez J; Bermejo Vicedo T
Farm Hosp; 2013; 37(3):265-6. PubMed ID: 23789804
[No Abstract] [Full Text] [Related]
18. Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children.
Ramaswamy K; Hsieh L; Leven E; Thompson MV; Nugent D; Bussel JB
J Pediatr; 2014 Sep; 165(3):600-5.e4. PubMed ID: 24857517
[TBL] [Abstract][Full Text] [Related]
19. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
Tamary H; Roganovic J; Chitlur M; Nugent DJ
Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
[TBL] [Abstract][Full Text] [Related]
20. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]